Last reviewed · How we verify
NCT03979066: NEOiPANC
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
Phase 2 trial testing Atezolizumab in Pancreatic Ductal Adenocarcinoma in 1 participant. Terminated before completion.
3 November 2019
Quick facts
| Lead sponsor | Gulam Manji |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 1 November 2019 |
| Primary completion | 3 November 2019 |
| Estimated completion | 3 November 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Atezolizumab (atezolizumab) — full drug profile →
- PEGPH20 — full drug profile →
Conditions studied
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
Sponsor
Gulam Manji
Who can join
Adults 18 to 99, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor rather than increase the chance of cure.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting the tumor stroma for cancer therapy.
Xu M, Zhang T, Xia R, Wei Y, et al · · 2022 · cited 195× · PMID 36324128 · DOI 10.1186/s12943-022-01670-1 -
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.
Marei HE, Hasan A, Pozzoli G, Cenciarelli C. · · 2023 · cited 176× · PMID 37038154 · DOI 10.1186/s12935-023-02902-0 -
Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?
He Y, Liu T, Dai S, Xu Z, et al · · 2021 · cited 57× · PMID 34733848 · DOI 10.3389/fcell.2021.739161 -
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion.
Hilmi M, Nicolle R, Bousquet C, Neuzillet C. · · 2020 · cited 44× · PMID 33066357 · DOI 10.3390/cancers12102969 -
Immunological combination treatment holds the key to improving survival in pancreatic cancer.
Sodergren MH, Mangal N, Wasan H, Sadanandam A, et al · · 2020 · cited 20× · PMID 32748119 · DOI 10.1007/s00432-020-03332-5 -
Targeting the Stroma in the Management of Pancreatic Cancer.
Edwards P, Kang BW, Chau I. · · 2021 · cited 19× · PMID 34336679 · DOI 10.3389/fonc.2021.691185 -
Predicting and Monitoring Immune Checkpoint Inhibitor Therapy Using Artificial Intelligence in Pancreatic Cancer.
Yu G, Zhang Z, Eresen A, Hou Q, et al · · 2024 · cited 4× · PMID 39596108 · DOI 10.3390/ijms252212038 -
Neoadjuvant Therapy or Upfront Surgery for Pancreatic Cancer-To Whom, When, and How?
Kwaśniewska D, Fudalej M, Badowska-Kozakiewicz AM, Czerw A, et al · · 2025 · cited 1× · PMID 40805279 · DOI 10.3390/cancers17152584
Verify or expand the search:
- PubMed search for NCT03979066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Atezolizumab
Trials testing the same drug.
- NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other recruiting trials for Pancreatic Ductal Adenocarcinoma
Currently open trials in the same condition.
- NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
- NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting
Other Gulam Manji trials
Trials by the same sponsor.
- NCT02918162 — Perioperative Chemo and Pembrolizumab in Gastric Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03979066 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gulam Manji
- Last refreshed: 23 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03979066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing